By Stephen Nakrosis
The American depositary receipts of Biodexa Pharmaceuticals were trading in the green in Tuesday's after-hours session, following news the Nasdaq Hearings panel approved the company's request for more time to regain compliance with continued listing requirements.
In the late-trading session, Biodexa's ADRs were trading 53% higher, at $7.65. They ended the day with a 4% loss, closing at $5.01.
The company sought to extend the time it was given to regain compliance with the exchange's $1 minimum bid price requirement.
In September, Biodexa announced a change in its ADR to share ratio from 1 ADR representing 400 shares to 1 ADR representing 10,000 shares. That change took effect earlier this month.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 15, 2024 17:50 ET (21:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。